A detailed history of First Command Bank transactions in Mi Nk Therapeutics, Inc. stock. As of the latest transaction made, First Command Bank holds 1,031 shares of INKT stock, worth $752. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,031
Holding current value
$752
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 21, 2023

BUY
$0.89 - $3.33 $917 - $3,433
1,031 New
1,031 $2,000

Others Institutions Holding INKT

About MiNK Therapeutics, Inc.


  • Ticker INKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,775,100
  • Market Cap $24.7M
  • Description
  • MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...
More about INKT
Track This Portfolio

Track First Command Bank Portfolio

Follow First Command Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Command Bank, based on Form 13F filings with the SEC.

News

Stay updated on First Command Bank with notifications on news.